Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.50 | 4,955 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 20.00 | 21.00 | 20.50 | 20.50 | 20.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Electronic Computers | 1.03M | -2.92M | -0.2188 | -0.94 | 2.73M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:12:49 | O | 4,955 | 20.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 06/11/2024 | 07:00 | UK RNS | Feedback PLC Result of WRAP Retail Offer |
| 04/11/2024 | 15:46 | UK RNS | Feedback PLC Successful Fundraising upscaled to c. £5.57m |
| 04/11/2024 | 12:21 | ALNC |  Feedback annual loss widens amid placing and reorganisation of shares |
| 04/11/2024 | 07:02 | UK RNS | Feedback PLC WRAP Retail Offer for up to £1 million |
| 04/11/2024 | 07:01 | UK RNS | Feedback PLC Proposed Fundraise & Share Capital Reorganisation |
| 04/11/2024 | 07:00 | UK RNS | Feedback PLC Final Results |
| 16/10/2024 | 09:34 | ALNC | Feedback shares jump as unlocks NHS reimbursement mechanism |
| 16/10/2024 | 06:00 | UK RNS | Feedback PLC Elective Recovery Fund funding mechanism |
| 19/9/2024 | 15:51 | ALNC | Feedback inks collaboration deal to streamline NHS referrals |
| 19/9/2024 | 06:00 | UK RNS | Feedback PLC Collaboration Agreement |
Feedback (FDBK) Share Charts1 Year Feedback Chart |
|
1 Month Feedback Chart |
Intraday Feedback Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 18/11/2024 | 16:33 | FEEDBACK plc Medical Imaging Technology | 11,578 |
| 04/11/2019 | 07:39 | Feedback | 35 |
| 01/11/2018 | 15:33 | ****Feedback PLC**** | 3,006 |
| 03/2/2010 | 11:50 | Feedback looks interesting - could easily be a ten bagger over next year | 396 |
| 03/9/2002 | 10:53 | ainsley long .........................quick shart it | 2 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 08:12:51 | 20.00 | 4,955 | 991.00 | O |
| 2024-11-20 12:18:01 | 20.27 | 950 | 192.53 | O |
| 2024-11-20 11:23:10 | 20.10 | 2,793 | 561.39 | O |
| Top Posts |
|---|
Posted at 05/11/2024 13:06 by yump I thought about 12 months worth of working capital, but given the way revenue from the collaboration is likely to flow, not enough.Saving grace might be if any sort of initial contract payment is likely to cover some costs before there’s a flow of patients that results in the per-patient payments. Never know - perhaps a likely or guaranteed number of patients can be pre-paid from the funding. I can’t believe that any business would enter into a committment without any guaranteed payment. FDBK isn’t a travelling salesman working purely on commission. |
Posted at 04/11/2024 13:24 by martinmc123 2*Feedback plc, the clinical infrastructure specialist, posted FY results for the 12 months to 31 May 2024 this morning and these were pretty poor. Headline revenue performance was strong with a 15% increase in revenue to £1.18m (2023: £1.02m) with Bleepa® contributing 87% of the total. But sales were down to £0.95m from 2023: £1.27m, a drop of around 25%. And the Group slid further into loss as well with EBITDA loss increasing to £2.73m from 2023: £2.61m... ...from WealthOracle wealthoracle.co.uk/d |
Posted at 04/11/2024 07:51 by yump But TO says “there’s no better time to invest in the company”.I guess that’s why the issue price is 20p. I think a few of us thought a placing would be coming because the new amazing collaboration only gets paid per patient. So FDBK have to install Bleepa/Carelocker at their expense and hope enough clinicians use it with patients to make it pay. All the financial risk is now with FDBK. Written off my investment. This will die a long slow death. |
Posted at 01/11/2024 16:07 by pugugly FDBK not in the top 20 holdings |
Posted at 01/11/2024 16:02 by ducatiman Other stocks where Miton are shareholders are displaying a similar pattern to recent Fdbk movements.Hopefully all will bounce when they have finished selling as sadly I’m involved with a few of them. |
Posted at 21/10/2024 14:14 by ged5 Quite a bit of interest in FDBK today. Didn't Streeting speak about the NHS earlier?Is the profit-taking over? Certainly looks oversold to me. Just that gap just below 40p may put some off but will the news be more enticing? Place your bets at this stage. See you're posting over on ENSI, Yump. Looks interesting to me. |
Posted at 16/10/2024 08:28 by yump I will have to re-read it though !This bit is hidden in there: “ the more activity delivered and diversions achieved the more an ICB will be reimbursed” So the money appears to FOLLOW the activity. ie. Feedback provide the service and then get paid later, depending on no. of patients. That would be very good for securing repeat revenues IF the throughput is sufficient, but it appears to require up front spend from feedback. Existing contracts presumably will be moved or renewed on that basis, which takes them out of annual renewal capital spend and potential risk of being cut. No FDBK spend involved there hopefully. Although this new funding runs out in March 2025. If these new fangled contracts with a new ICB or trust don’t have a capital element, then Feedback is going to have to fund them with its own capital initially. The contracts may have zero committed value, with just a per patient clause. So the risk is all transferred to Feedback and success depends on whether clinicians buy into it or not. Lots of words in the RNS, but not the ones that matter to shareholders. I suspect the next step may be a series of announcements of “contractsR The implementation is clearly not going to fund itself. |
Posted at 16/10/2024 06:40 by yump Sort of good news - perhaps.So ring fenced and diverted capital budgets are supposedly an obstacle. Now there is a fund in revenue spend for diverting patients away from normal outpatient process. That doesn’t answer the question of how many trusts are interested but stuck with the capital spend problem. That is what I want to know. We have never been told that crucial information. It also doesn’t cover the overall process of implementing Bleepa in a location, because its per-patient funding. Can a trust get advance funding for a prospective number of patients, or does FDBK have to carry the implementaion spend/effort before any cash is forthcoming - and that depends on patient flow. So is there a contract committment from a trust ? Without it FDBK will be like a charity and so will shareholders. The fact that they need an implementation partner makes me think they have been useless in getting even committment in principle from more tham a handful of trusts. |
Posted at 28/5/2024 17:17 by ydderf LR2 you had some questions and made assertions about Nimble in the other place. This below should help you with your worries:"Imaging Biometrics, LLC data security statement (2024-05-28): Imaging Biometrics (IB) and its developed software applications (apps) comply with the requirements of the US HIPAA and the EU GDPR regulations. IB applies the principles outlined in the US FDA cybersecurity guidance to all the software apps it develops, whether or not a given app is technically classified as a medical device. IB is evaluating the changes in the newly-released revision 3 of the US NIST share price 800-171r3 standard for integration into its policies, procedures, and software development process. Similarly, IB is pursuing implementation of the recommendations contained in the NIST share price 800-218 secure software development framework and ISO 27001 information security standards. Note IB does not host the data accessed via IB Nimble. All data is hosted by the implementing client institution within its data center and is also subject to the institution’s privacy and information security policies and practices." You're welcome! Perhaps you share with the LSE posters you engaged with recently? You were commenting upon this RNS: |
Posted at 15/11/2022 16:25 by chopper harris1 What the hell wwre they thinking of with the 200:1 consolidation?10:1?, yes, possibly, if they wanted to make some kind of statement which might have taken the FDBK share price a little out of typical penny share territory in the eyes of some. But 200:1? Sheer bloody madness which has almost certainly given most of us very little chance of ever getting our money back. Which clowns gave our hapless FDBK chumps this advice? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
